TY - JOUR T1 - Dopaminergic stimulants and risk of Parkinson’s disease JF - medRxiv DO - 10.1101/2020.05.06.20089748 SP - 2020.05.06.20089748 AU - Michael Wainberg AU - Dipender Gill AU - Bowen Su AU - Mike A. Nalls AU - Robert R. Graham AU - Sudeshna Das AU - Ioanna Tzoulaki AU - Nasa Sinnott-Armstrong AU - Manuel A. Rivas Y1 - 2020/01/01 UR - http://medrxiv.org/content/early/2020/05/11/2020.05.06.20089748.abstract N2 - Parkinson’s disease is characterized by dopaminergic neurodegeneration in the substantia nigra. Although dopaminergic drugs are the mainstay of Parkinson’s treatment, their putative disease-modifying properties remain controversial. We explored whether prescription of dopaminergic stimulants for attention-deficit hyperactivity disorder (ADHD) might affect Parkinson’s incidence. We performed Cox survival analyses for outpatient Parkinson’s diagnosis among ADHD-diagnosed seniors in the Optum Clinformatics™ Data Mart de-identified administrative claims database, correcting for diverse demographic and socio-economic status covariates. We compared 5,683 sustained users (≥ 90 days) of dopaminergic stimulants to 252 sustained users of atomoxetine, a noradrenergic first-line ADHD medication. Parkinson’s incidence was reduced among sustained dopaminergic stimulant users compared to atomoxetine users (adjusted hazard ratio [HR] 0.15, 95% confidence interval [CI] 0.04-0.56, p = 0.005). Effect sizes were comparable between derivatives of amphetamine (adjusted HR 0.12, 95% CI 0.03-0.48, p = 0.003) and methylphenidate (adjusted HR 0.27, 95% CI 0.04-1.76, p = 0.2). In sensitivity analyses, similar trends were observed when other psychotropics (SSRIs, gabapentin) were used as comparators instead of atomoxetine, or when the threshold for sustained use was defined as 45, 180 or 360 days instead of 90. Thus, sustained dopaminergic stimulant use was associated with lower Parkinson’s incidence among seniors with ADHD. Our results are consistent with a protective effect of dopaminergic stimulants on the development of Parkinson’s, and support a re-examination of certain dopaminergics, particularly rasagiline and other selective monoamine oxidase B inhibitors, as potential disease-modifying agents.Competing Interest StatementThe authors have declared no competing interest.Funding StatementThis work was supported by a Stanford Bio-X Bowes Fellowship (to M.W.), Stanford Graduate Fellowship (to N.S.-A.), and National Defense Science & Engineering Graduate Fellowship (to N.S.-A.). M.A.N.’s participation in this work was supported in part by a consulting contract between Data Tecnica International and the National Institute on Aging. Data access for this project was provided by the Stanford Center for Population Health Sciences Data Core. The PHS Data Core is supported by a National Institutes of Health National Center for Advancing Translational Science Clinical and Translational Science Award (UL1 TR001085) and internal Stanford funding. M.A.R. is supported by Stanford University, a National Institute of Health center for Multi- and Trans-ethnic Mapping of Mendelian and Complex Diseases grant (5U01 HG009080), and the National Human Genome Research Institute of the National Institutes of Health under Award Number R01HG010140. The content is solely the responsibility of the authors and does not necessarily represent the official views of the NIH.Author DeclarationsAll relevant ethical guidelines have been followed; any necessary IRB and/or ethics committee approvals have been obtained and details of the IRB/oversight body are included in the manuscript.YesAll necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesOptum Clinformatics™ Data Mart is available by application through the Stanford Center for Population Health Sciences (http://med.stanford.edu/phs.html). ER -